Appointment comes amid a growing US footprint
Tampere, Finland, April 22, 2022—Combinostics, the only company providing a complete solution from early detection and diagnosis to the ongoing management of neurological disorders, today announced that Tom Gardner has joined Combinostics as the Vice President of US Sales.
“We’re thrilled to welcome Tom to our growing leadership team,” said Richard Hausmann, CEO of Combinostics. “Tom brings over 25 years of experience in successfully developing and leading sales teams in the AI and clinical imaging software solutions space, making him well-suited to help Combinostics continue expanding our footprint in the US and supporting more clinicians in their care of patients with neurological disorders.”
Combinostics solutions combine innovative AI technology with a holistic view of patient data to enable clinicians to make reliable, confident, evidence-based decisions for the diagnosis and management of patients with neurological disorders. The cMRI™ application supports radiologists with AI-enabled imaging quantification, while the cDSI™ application combines and analyzes key patient and demographic data to support diagnosis, testing decisions, prediction of disease trajectory, and treatment management.
Tom brings an extensive medical imaging background with a long track record of leading sales teams through high growth periods. Throughout Tom’s career, he has worked closely with cardiac surgeons, cardiologists and radiologists, from private physician practices to large, complex health systems. In his most recent role, Tom served as the Regional Vice President of Sales for AI echocardiography analysis provider Ultromics, where he established a go-to-market strategy for new, cloud-based AI technology. Prior to his work at Ultromics, Tom was the Senior Director of Sales and Clinical Applications in North America for Circle Cardiovascular Imaging, overseeing record growth over a four-year period. Tom has a bachelor’s degree in corporate finance from the University of North Texas and an MBA from the Cox School of Business at Southern Methodist University in Dallas, TX.
“The expert team at Combinostics has developed an incredible AI platform unlike any other solution in the market, and I have never been more optimistic about the ability of AI to make a difference in patients’ lives,” said Tom. “I’m excited to contribute my specific experience introducing innovative software solutions to Combinostics’ future growth as our focus intensifies on customer-centric solutions and the millions of patients affected by neurological disorders.
To learn more about Combinostics’ products, visit booth 109 at The American Society of Neuroradiology (ASNR)’s Annual Meeting, May 14-18, 2022, in New York City. Schedule a meeting at www.combinostics.com/ASNR.
Combinostics’ AI-powered cNeuro suite of products helps clinicians make a difference in the lives of patients with neurological disorders. By quantifying brain images and integrating patient data from multiple sources with insights from previous patients, the company’s unique software tools provide radiologists and clinicians the support they need for confident, evidence-based diagnostic and management decisions. The company was founded in 2014 and is headquartered in Tampere, Finland. For more information, please visit combinostics.com.